Friday, Nov. 20, 2015, 93 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $23.06 to $5,010,000.00.

Highlighted Stocks Traded by Insiders:

Salesforce.com (CRM) - FREE Research Report

Benioff Marc, who is Chairman of the Board & CEO at Salesforce.com, sold 25,000 shares at $81.22 on Nov. 20, 2015. Following this transaction, the Chairman of the Board & CEO owned 37.3 million shares meaning that the stake was reduced by 0.07% with the 25,000-share transaction.

The shares most recently traded at $80.60, down $0.62, or 0.77% since the insider transaction. Historical insider transactions for Salesforce.com go as follows:

  • 4-Week # shares sold: 228,516
  • 12-Week # shares sold: 401,972
  • 24-Week # shares sold: 410,021

The average volume for Salesforce.com has been 4.0 million shares per day over the past 30 days. Salesforce.com has a market cap of $53.2 billion and is part of the technology sector and computer software & services industry. Shares are up 36.55% year-to-date as of the close of trading on Friday.

salesforce.com, inc. provides enterprise cloud computing solutions, with a focus on customer relationship management to various businesses and industries worldwide. Currently, there are 27 analysts who rate Salesforce.com a buy, 1 analyst rates it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CRM - FREE

TheStreet Quant Ratings

rates Salesforce.com as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and compelling growth in net income. However, as a counter to these strengths, we also find weaknesses including generally higher debt management risk and weak operating cash flow. Get the full

Salesforce.com Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

HHGregg (HGG) - FREE Research Report

Riesbeck Robert James, who is Chief Financial Officer at HHGregg, bought 100,000 shares at $3.83 on Nov. 20, 2015. Following this transaction, the Chief Financial Officer owned 200,000 shares meaning that the stake was boosted by 100% with the 100,000-share transaction.

The shares most recently traded at $4.00, up $0.17, or 4.25% since the insider transaction. Historical insider transactions for HHGregg go as follows:

  • 4-Week # shares bought: 5,000
  • 4-Week # shares sold: 83,507
  • 12-Week # shares bought: 5,000
  • 12-Week # shares sold: 83,507
  • 24-Week # shares bought: 5,000
  • 24-Week # shares sold: 83,507

The average volume for HHGregg has been 109,100 shares per day over the past 30 days. HHGregg has a market cap of $103.6 million and is part of the services sector and specialty retail industry. Shares are down 47.82% year-to-date as of the close of trading on Friday.

hhgregg, Inc. operates as an appliance, consumer electronics, and furniture retailer. Currently, there are no analysts who rate HHGregg a buy, no analysts rate it a sell, and 9 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on HGG - FREE

TheStreet Quant Ratings

rates HHGregg as a

sell

. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, generally disappointing historical performance in the stock itself and poor profit margins. Get the full

HHGregg Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Cambrex (CBM) - FREE Research Report

Korb William B, who is Director at Cambrex, sold 10,000 shares at $50.18 on Nov. 20, 2015. Following this transaction, the Director owned 36,562 shares meaning that the stake was reduced by 21.48% with the 10,000-share transaction.

The shares most recently traded at $51.07, up $0.89, or 1.74% since the insider transaction. Historical insider transactions for Cambrex go as follows:

  • 4-Week # shares sold: 1,000
  • 12-Week # shares sold: 1,000
  • 24-Week # shares sold: 5,956

The average volume for Cambrex has been 466,100 shares per day over the past 30 days. Cambrex has a market cap of $1.5 billion and is part of the health care sector and drugs industry. Shares are up 132.1% year-to-date as of the close of trading on Friday.

Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. The company has a P/E ratio of 23.2. Currently, there is 1 analyst who rates Cambrex a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on CBM - FREE

TheStreet Quant Ratings

rates Cambrex as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and notable return on equity. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full

Cambrex Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.